Journal of Chemical Technology & Biotechnology · 2018 · 33 citations · 65 references
Life SciencesImmunologyOncologyCell TherapyImmunotechnologyImmunotherapyCancer ImmunotherapyCell ManufacturingCell Therapy ManufacturingCell-based TherapeuticsChimeric AntibodiesChimeric Antigen Receptor T-cell TherapyAutologous Car T-cell TherapyCar T Cell TrialsChimeric Antigen Receptor T Cell ManufacturingClinical Development StrategyHematologic Malignancy Car T-cell TherapyScientific InvestigationT-cell ManufacturingT-cell Therapy
Abstract Recent accelerated approvals of Chimeric Antigen Receptor T‐cell (CAR‐T) therapies targeting refractory haematological malignancies underscore the potential for this novel technology platform to provide new therapeutic options for oncology areas with high unmet medical needs. However, these powerful ‘living drugs’ are markedly different to conventional small molecule and biologic therapies on several levels. The highly complex nature and varied composition of CAR‐T based products still requires considerable investigation to resolve the best approaches to ensure reproducible and cost‐effective manufacture, clinical development, and application. This review will focus on key issues for manufacturing and quality control of these exciting new therapeutic modalities, preceded by a brief description of CAR principals and clinical development considerations. © 2018 The Authors. Journal of Chemical Technology & Biotechnology published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
65
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · New England Journal of Medicine · 2017 · 5.9K citations · Full text
Medicine, Hematology, Oncology +16
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner et al. · New England Journal of Medicine · 2018 · 5.6K citations · Full text
Medicine, Hematology, Oncology +17
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Cameron J. Turtle, Laïla‐Aïcha Hanafi, Carolina Berger et al. · Journal of Clinical Investigation · 2016 · 2.1K citations · Full text
Medicine, Immunology, Oncology +17
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Justin Eyquem, Jorge Mansilla‐Soto, Theodoros Giavridis et al. · Nature · 2017 · 1.8K citations · Full text